Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:30:12 EDT Tue 01 Jul 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:CSTL
- CASTLE BIOSCIENCES INC -
https://ir.castlebiosciences.com/
20:30:12 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
CSTL
- Q
0.1
19.75
·
20.50
0.1
20.34
-0.08
-0.4
353.2
6,942
4,747
20.25
20.58
20.0101
35.84 15.45
16:10:03
Jun 19
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 4747
More trades...
Time ET
Ex
Price
Change
Volume
16:10:03
Q
20.34
-0.08
1
16:10:03
Q
20.34
-0.08
1
16:04:12
Q
20.34
-0.08
1
16:04:11
Q
20.34
-0.08
1
16:04:11
Q
20.34
-0.08
1
16:04:09
Q
20.34
-0.08
1
16:04:06
Q
20.34
-0.08
1
16:04:03
Q
20.34
-0.08
1
16:02:06
Q
20.34
-0.08
153
16:02:06
Q
20.34
-0.08
135
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-06-19 07:00
U:CSTL
News Release
200
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-16 16:30
U:CSTL
News Release
200
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
2025-06-11 07:00
U:CSTL
News Release
200
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
2025-06-04 07:00
U:CSTL
News Release
200
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards(TM)
2025-05-29 16:30
U:CSTL
News Release
200
New Data at ASCO 2025 Affirms DecisionDx(TM)-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
2025-05-21 07:00
U:CSTL
News Release
200
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
2025-05-09 07:00
U:CSTL
News Release
200
Real-World Study Confirms Long-Term Performance of DecisionDx(TM)-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
2025-05-07 07:00
U:CSTL
News Release
200
Castle Biosciences Celebrates Skin Cancer Awareness Month
2025-05-05 16:06
U:CSTL
News Release
200
Castle Biosciences Reports First Quarter 2025 Results
2025-05-05 16:05
U:CSTL
News Release
200
Castle Biosciences to Acquire Previse
2025-05-02 16:30
U:CSTL
News Release
200
New Data at DDW 2025 Further Demonstrates the TissueCypher(TM) Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
2025-04-30 17:00
U:CSTL
News Release
200
New Study Shows Castle Biosciences' DecisionDx(TM)-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
2025-04-28 07:00
U:CSTL
News Release
200
DecisionDx(TM)-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
2025-04-25 16:15
U:CSTL
News Release
200
New Data at AACR Annual Meeting Highlights Use of DecisionDx(TM)-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
2025-04-14 07:00
U:CSTL
News Release
200
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
2025-04-08 07:00
U:CSTL
News Release
200
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
2025-04-07 07:00
U:CSTL
News Release
200
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
2025-04-03 07:00
U:CSTL
News Release
200
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx(TM)-Melanoma Test
2025-04-01 16:30
U:CSTL
News Release
200
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx(TM)-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
2025-03-28 16:15
U:CSTL
News Release
200
Castle Biosciences' DecisionDx(TM)-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups